News

pharmaphorum2y
ImmunoGen ELAHERE wins accelerated FDA approval for ovarian cancer
ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...
Hosted on MSN1mon
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
Following the approval, Elahere became the first and only FRα-directed antibody drug conjugate (ADC) approved specifically for patients with FRα positive, platinum-resistant ovarian cancer in ...
pharmaphorum1d
AbbVie builds the case for ovarian cancer drug Elahere
The new survival data comes as AbbVie is already seeing strong take-up of Elahere, which was the centrepiece of its $10.1 billion takeover of ImmunoGen in 2023. The drug was given accelerated ...
Barchart on MSN2d
Are Wall Street Analysts Predicting AbbVie Stock Will Climb or Sink?
AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a biopharmaceutical company discovers, develops, ...
AbbVie Q1 Earnings Review: Typically Strong Performance, Aesthetics Aside
AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...
AbbVie spikes as Q1 beat prompts guidance raise
AbbVie (ABBV) stock gains as the company lifts 2025 earnings outlook after strong Q1 results, driven by its newer immunology ...